Table 1

Patient characteristics

CD19-CAR-T cells (n=8)Rituximab (n=5)
Demographic characteristics
Age, years mean (SD)33.2 (9.6)56.8 (7.56)
Sex, female (n)72
Type of autoimmune disease (n)
 SLE60
 SSc22
 GPA03
Disease duration, months mean (SD)72.7 (64.96)44.4 (50.31)
Autoantibodies to (n)
 ANA83
 dsDNA60
 Scl-7021
 Histone41
 pANCA01
 cANCA03
 Others*51
Organ involvement (n)
 Mucocutaneous82
 Pulmonary44
 Gastrointestinal11
 Cardiovascular21
 Renal52
 MSK30
 ENT02
 Haematological†60
RTX duration, months mean (SD)20.2 (29.65)
Immunosuppressive medication (n)
 Glucocorticoid01
 Other drugs01
  • Categorical variables: numbers, continuous variables: mean, (SD).

  • *Each one reactivity in CD19-CAR-T cells: anti-Smith; anti-RNP; anti-SSA/Ro52; anti-SSA/Ro60; anti-SSB; antinucleosome; each one reactivity in RTX: rheumatoid factor.

  • †Haematological involvement: anaemia 2/6 (1 with evidence of haemolysis), thrombocythemia 1/6, lymphopenia 6/6 according to Easy-BILAG definition.48

  • ANA, antinuclear antibodies; antiSSA/Ro52, anti-Sjögren’s syndrome-related antigen A autoantibodies/Ro52; cANCA, antineutrophil cytoplasmic antibodies with diffuse granular, cytoplasmic staining pattern; CAR-T, chimeric antigen receptor T cells; dsDNA, double-stranded DNA; ENT, ear–nose–throat disease; GPA, granulomatosis polyangiitis; MSK, musculoskeletal disease; pANCA, antineutrophil cytoplasmic antibodies with peripheral staining pattern; RNP, ribonucleoprotein; RTX, rituximab; Scl-70, scleroderma 70; SLE, systemic lupus erythematosus; SSA/Ro60, anti-Sjögren’s syndrome-related antigen A/Ro60; SSB, anti-Sjogren’s syndrome-related antigen B; SSc, systemic sclerosis.